Anteris Technologies (AVR) EGM 2024 summary
Event summary combining transcript, slides, and related documents.
EGM 2024 summary
12 Jan, 2026Opening remarks and agenda
Meeting opened with a welcome to both in-person and online attendees, chaired by John Seaberg from Minneapolis.
Acknowledgement of traditional custodians of country in Australia and explanation of hybrid meeting format.
Agenda included the EGM, followed by Share Scheme and Option Scheme Meetings.
Confirmation of quorum and introduction of attending directors.
Outline of meeting procedures, including voting and question submission protocols.
Specific resolutions to be voted on
Resolution 1: Ratification of prior issue of 1,875,000 ATL shares under ASX Listing Rule 7.1.
Resolution 2: Ratification of prior issue of 41,000 ATL shares to Evolution Capital Pty Limited under ASX Listing Rule 7.1.
Voting exclusions for each resolution were noted as per the Notice of Meeting.
Corporate governance
Poll voting conducted on all resolutions to enhance transparency and governance.
Appointment of Lewis Brimelow as returning officer for the meeting.
Chair declared intent to vote all undirected proxies in favor of all items.
Latest events from Anteris Technologies
- A novel TAVR valve with proven durability and clinical benefits targets major market expansion.AVR
Barclays 28th Annual Global Healthcare Conference10 Mar 2026 - 2025 net loss widened to $94.2M on higher R&D, but liquidity strengthened by $320M in new equity.AVR
H2 20258 Mar 2026 - DurAVR demonstrates clinical superiority and rapid trial momentum, reshaping the TAVR landscape.AVR
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - Shareholders considered and voted on a US redomicile scheme, with results pending ASX release.AVR
Share Scheme Meeting12 Jan 2026 - Option holders voted on exchanging Anteris options for ATGC options; results pending ASX release.AVR
Option Scheme Meeting12 Jan 2026 - Biomimetic TAVR valve targets $10B market with superior hemodynamics and pivotal study launch.AVR
Barclays 27th Annual Global Healthcare Conference26 Dec 2025 - OJEMDA's rapid adoption and robust pipeline drive steady growth and future market potential.AVR
TD Cowen 45th Annual Healthcare Conference26 Dec 2025 - US IPO, expanded R&D, and board expertise marked a pivotal year; all proposals recommended.AVR
AGM 202513 Dec 2025 - Regulatory approvals advanced the PARADIGM Trial, driving higher R&D spend and cash outflows.AVR
Q3 2025 TU23 Nov 2025